ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2019
Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice.CPT: pharmacometrics & systems pharmacology · 2024Pooled it
- Protein Modifications for Cellular Protein Delivery.Chemical reviews · 2026Review
- Defining Composition-Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed Immunogenicity.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Targeting macropinocytosis for cancer therapy.Nature reviews. Cancer · 2026Review
- Effects of Polysaccharide Coating on Cell-Surface Association and Endocytic Uptake of PLGA Nanomicelles in MCF-7 Cells.Pharmaceutics · 2025Article
- KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Nanomedicine (London, England) · 2025Review
- The coiled-coil protein carrier structure affects the activation of certain endocytosis pathways.RSC advances · 2025Article
- Oncogenic β-catenin stimulation of cofilin 1-mediated macropinocytosis is druggable for cancer.Theranostics · 2025Article
- RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment.Nature communications · 2024Article
- Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody.Scientific reports · 2024Article
- A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation ofFrontiers in pharmacology · 2024Article
- A Comparison of Cellular Uptake Mechanisms, Delivery Efficacy, and Intracellular Fate between Liposomes and Extracellular Vesicles.Advanced healthcare materials · 2023Review
- Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.Cell reports. Medicine · 2023Article
- Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Hemopexin as a Potential Binding Partner of Arginine-Rich Cell-Penetrating Peptides in Serum.ACS pharmacology & translational science · 2022Article
- GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-CaJournal of nanobiotechnology · 2022Article
- Piezo1 activation using Yoda1 inhibits macropinocytosis in A431 human epidermoid carcinoma cells.Scientific reports · 2022Article
- Mechanisms of Uptake and Membrane Curvature Generation for the Internalization of Silica Nanoparticles by Cells.Nano letters · 2022Article
- Report on Webinar Series Cell and Gene Therapy: From Concept to Clinical Use.Pharmaceutics · 2022Article
- Exploiting cancer's drinking problem: regulation and therapeutic potential of macropinocytosis.Trends in cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acids are a rapidly emerging therapeutic modality with the potential to become the third major drug modality alongside antibodies and small molecules. Owing to the unfavourable physico-chemical characteristics of nucleic acids, such as large size and negative charge, intracellular delivery remains a fundamental challenge to realizing this potential. Delivery technologies such as lipids, polymers and peptides have been used to facilitate delivery, with many of the most successful technologies using macropinocytosis to gain cellular entry; mostly by default rather than design. Fundamental knowledge of macropinocytosis is rapidly growing, presenting opportunities to better tailor design strategies to target this pathway. Furthermore, certain types of tumour cells have been observed to have high levels of macropinocytic activity and traffic cargo to favourable destinations within the cell for endosomal release, providing unique opportunities to further use this entry route for drug delivery. In this article, we review the delivery systems reported to be taken up by macropinocytosis and what is known about the mechanisms for regulating macropinocytosis in tumour cells. From this analysis, we identify new opportunities for exploiting this pathway for the intracellular delivery of nucleic acids to tumour cells. This article is part of the Theo Murphy meeting issue 'Macropinocytosis'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.